Research & Development
With more than 15 years of expertise in helping patients with rare and debilitating diseases, we keep innovating to improve their health and quality of life. We steadfastly work towards the expansion of our product pipeline by capitalizing on drug development opportunities and continually investing in mutually gratifying strategic alliances.
In partnership with the renowned research organization the Population Council, Medunik Canada investigates the remyelination ability of a synthetic progestin.
Éric Gervais
President of DPG
“Leveraging DPG’s unique expertise and rich scientific heritage in women’s health, Medunik Canada brings the Group’s R&D activities to new heights while continuing to close the gap on women’s health. Striving to find solutions for the complex challenges in debilitating diseases, Médunik Canada and the Population Council are well positioned to lead this project with potential global impact, changing the lives of millions affected by Multiple Sclerosis, three-quarters of whom are women”.